EX229

• Description :

  EX229, a Benzimidazole derivative, is a potent and allosteric activator of AMP-activated protein kinase (AMPK), with Kds of 0.06 μM, 0.06 μM and 0.51 μM for α1β1γ1, α2β1γ1 and α1β2γ1 in biolayer interferometry, respectively.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  AMPK

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; PI3K/Akt/mTOR

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/EX229.html

• Purity :

  99.44

• Solubility :

  DMSO : 13 mg/mL (ultrasonic; warming)

• Smiles :

  O=C(O)C1=CC(OC2=NC3=CC(Cl)=C(C4=CC5=C(N(C)C=C5)C=C4)C=C3N2)=CC=C1C

• Molecular Formula :

  C24H18ClN3O3

• Molecular Weight :

  431.87

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Xiao B, et al. Structural basis of AMPK regulation by small molecule activators. Nat Commun. 2013;4:3017.|[2]Bultot L, et al. Benzimidazole derivative small-molecule 991 enhances AMPK activity and glucose uptake induced by AICAR or contraction in skeletal muscle. Am J Physiol Endocrinol Metab. 2016 Oct 1;311 (4) :E706-E719.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  AMPK α1β1γ1; AMPK α1β2γ1; AMPK α2β1γ1

• CAS Number :

  [1219739-36-2]